Nanoscale Liposomes Co‐Loaded with Irinotecan Hydrochloride and Thalidomide for Colorectal Cancer Synergistic Therapy
Macromolecular Bioscience · 2025
DOI: 10.1002/mabi.202400478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Bioscience, 2025. Verfasst von Xuanrong Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals & College of Pharmaceutical Science, Zhejiang University of Techn…. Hauptthemen laut MEDLINE: Irinotecan, Liposomes, Colorectal Neoplasms, Thalidomide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China, Foundation of Zhejiang University of Technology.
Abstract (Originalsprache)
Irinotecan hydrochloride (CPT‐11) is one of the first‐line drugs used in the clinical treatment of colorectal cancer (CRC). However, the concomitant adverse effect of delayed diarrhea has hindered its clinical use. CPT‐11 combined with Thalidomide (THA) therapy is considered a palliative strategy. To optimize the synergistic treatment of CPT‐11 and THA, co‐loaded liposomes are constructed using cholesterol, lecithin, and 1, 2‐Distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐Poly(ethylene glycol) (DSPE‐PEG) as the “immune and gut microbiota regulator.” The co‐loaded liposomes, which possess good stability, are prepared by the solvent injection method. After the treatment with the co‐loaded liposomes, tumor growth in CRC‐bearing mice is significantly inhibited. In particular, the co‐loaded liposomes demonstrate favorable diarrhea‐relieving effects through the modulation of inflammatory cytokines and gut microbiota. These findings suggest that the co‐loaded liposomes have great potential as a combined drug‐delivery platform for CRC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals & College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, and Chemical Biology Center, Peking University, Xue Yuan Road No. 38, Beijing, 100191, China.
ORCID-Profile: Xuanrong Sun, Jie Shen
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
- Foundation of Zhejiang University of Technology
- China Postdoctoral Science Foundation
- Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
Zitieren
APA
Sun, X., Gong, Y., Xie, T., Fu, Z., Lu, D., Wei, B., Cai, Y., Yao, W., & Shen, J. (2025). Nanoscale Liposomes Co‐Loaded with Irinotecan Hydrochloride and Thalidomide for Colorectal Cancer Synergistic Therapy. Macromolecular Bioscience. https://doi.org/10.1002/mabi.202400478
Vancouver
Sun X, Gong Y, Xie T, Fu Z, Lu D, Wei B, et al. Nanoscale Liposomes Co‐Loaded with Irinotecan Hydrochloride and Thalidomide for Colorectal Cancer Synergistic Therapy. Macromolecular Bioscience. 2025. doi:10.1002/mabi.202400478
BibTeX
@article{Sun2025,
author = {Sun, Xuanrong and Gong, Yubei and Xie, Ting and Fu, Zixi and Lu, Dongze and Wei, Bin and Cai, Yue and Yao, Wenlong and Shen, Jie},
title = {Nanoscale Liposomes Co‐Loaded with Irinotecan Hydrochloride and Thalidomide for Colorectal Cancer Synergistic Therapy},
journal = {Macromolecular Bioscience},
year = {2025},
doi = {10.1002/mabi.202400478}
}
EUVIMED